Skip to main content
SpringerLink
Log in

Psychopharmacological Approaches

  • Chapter
  • First Online:
Handbook of Treatment-resistant Schizophrenia

  • 1098 Accesses

Abstract

Randomized clinical trials in patients with treatment-resistant schizophrenia have tested antipsychotic monotherapies, antipsychotic combination therapies, and nonantipsychotic augmentation strategies. Clozapine has been a landmark medication for patients with treatment-resistant schizophrenia, but attempts to specifically augment it have not resulted in any further breakthroughs of the same magnitude. Logical candidates for antipsychotic augmentation have in general not been successful, including anticholinesterase inhibitors and other agents used to treat cognitive decline in Alzheimer’s disease. Antipsychotic combinations have resulted in incremental improvements at best.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Citrome L. Treatment-refractory schizophrenia: what is it and what has been done about it? Neuropsychiatry. 2011;1:325-347.

    Google Scholar 

  2. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917-1928.

    Google Scholar 

  3. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30:531-540.

    Google Scholar 

  4. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055-1062.

    Google Scholar 

  5. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.

    Google Scholar 

  6. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.

    Google Scholar 

  7. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14:429-447.

    Google Scholar 

  8. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med. 2011;123:153-162.

    Google Scholar 

  9. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.

    Google Scholar 

  10. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159:255-262.

    Google Scholar 

  11. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.

    Google Scholar 

  12. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry. 1992;49:345-353.

    Google Scholar 

  13. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151:20-26.

    Google Scholar 

  14. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood‐onset schizophrenia. A double‐blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53:1090-1097.

    Google Scholar 

  15. Hong CJ, Chen JY, Chiu HJ, Sim CB. A double‐blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment‐refractory schizophrenia. Int Clin Psychopharmacol. 1997;12:123-130.

    Google Scholar 

  16. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337:809-815.

    Google Scholar 

  17. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155:751-760.

    Google Scholar 

  18. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6‐month randomized and double‐blind comparison. Arch Gen Psychiatry. 2001;58:965-972.

    Google Scholar 

  19. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry. 1998;155:499-504.

    Google Scholar 

  20. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment‐refractory schizophrenia. Am J Psychiatry. 1999;156:1374-1379.

    Google Scholar 

  21. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999;156:294-298.

    Google Scholar 

  22. Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R. Risperidone versus clozapine in treatment‐resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:911-922.

    Google Scholar 

  23. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158:1305-1313.

    Google Scholar 

  24. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double‐blind study. Int Clin Psychopharmacol. 2001;16:325-330.

    Google Scholar 

  25. Liberman RP, Gutkind D, Mintz J, et al. Impact of risperidone versus haloperidol on activities of daily living in the treatment of refractory schizophrenia. Compr Psychiatry. 2002;43:469-473.

    Google Scholar 

  26. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy‐refractory schizophrenia. Clin Neuropharmacol. 2005;28:163-168.

    Google Scholar 

  27. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;155:914-920.

    Google Scholar 

  28. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment‐resistant schizophrenia. Biol Psychiatry. 1999;45:403-411.

    Google Scholar 

  29. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ; Lilly Resistant Schizophrenia Study Group. Double‐blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry. 2001;49:52-63.

    Google Scholar 

  30. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr. The efficacy of high‐dose olanzapine versus clozapine in treatment‐resistant schizophrenia: a double‐blind crossover study. J Clin Psychopharmacol. 2003;23:668-671.

    Google Scholar 

  31. Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment‐resistant or treatment ‐intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:173-180.

    Google Scholar 

  32. Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 2005;162:124-129.

    Google Scholar 

  33. Shaw P, Sporn A, Gogtay N, et al. Childhood‐onset schizophrenia: a double‐blind, randomized clozapine‐olanzapine comparison. Arch Gen Psychiatry. 2006;63:721-730.

    Google Scholar 

  34. Meltzer HY, Bobo WV, Roy A, et al. A randomized, double‐blind comparison of clozapine and high-dose olanzapine in treatment‐resistant patients with schizophrenia. J Clin Psychiatry. 2008;69:274-285.

    Google Scholar 

  35. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high‐dose” olanzapine in refractory early‐onset schizophrenia: a 12‐week randomized and double‐blind comparison. Biol Psychiatry. 2008;63:524-529.

    Google Scholar 

  36. Emsley RA, Raniwalla J, Bailey PJ, Jones AM; PRIZE Study Group. A comparison of the effects of quetiapine (‘seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15:121-131.

    Google Scholar 

  37. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment‐resistant schizophrenia. Int Clin Psychopharmacol. 2006;21:21-28.

    Google Scholar 

  38. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;113:112-121.

    Google Scholar 

  39. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group. Aripiprazole for treatment‐resistant schizophrenia: results of a multicenter, randomized, double‐blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;68:213-223.

    Google Scholar 

  40. Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.

    Google Scholar 

  41. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63:622-629.

    Google Scholar 

  42. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.

    Google Scholar 

  43. Meltzer HY. Clozapine. Clin Schizophr Relat Psychoses. 2012;6:134-144.

    Google Scholar 

  44. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother. 2006;40:683-688.

    Google Scholar 

  45. Clozaril® (clozapine) [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; 2011.

    Google Scholar 

  46. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry. 2002;10:280-291.

    Google Scholar 

  47. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110:95-102.

    Google Scholar 

  48. Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med. 2008;120:18-33.

    Google Scholar 

  49. Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull. 1991;17:217-245.

    Google Scholar 

  50. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12:41-48.

    Google Scholar 

  51. Citrome L, Jaffe A, Levine J. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Am J Psychiatry. 2005;162:631.

    Google Scholar 

  52. Potter WZ, Ko GN, Zhang LD, Yan WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl). 1989;99(suppl):S87-S91.

    Google Scholar 

  53. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997;171:569-573.

    Google Scholar 

  54. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162:130-136.

    Google Scholar 

  55. Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66:63-72.

    Google Scholar 

  56. Honer WG, Thornton AE, Chen EY, et al; Clozapine and Risperidone Enhancement (CARE) Study Group. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.

    Google Scholar 

  57. Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007;92:90-94.

    Google Scholar 

  58. Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology. 2010;35:2274-2283.

    Google Scholar 

  59. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine‐induced hypersalivation in schizophrenia patients: a randomized, double‐blind, placebo-controlled cross‐over study. Int Clin Psychopharmacol. 2006;21:99-103.

    Google Scholar 

  60. Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41:24-28.

    Google Scholar 

  61. Genç Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapinequetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007;24:1-13.

    Google Scholar 

  62. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008;69:720-731.

    Google Scholar 

  63. Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13:1115-1125.

    Google Scholar 

  64. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.

    Google Scholar 

  65. Zink M, Kuwilsky A, Krumm B, Dressing H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23:305-314.

    Google Scholar 

  66. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebocontrolled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry. 2009;70:1348-1357.

    Google Scholar 

  67. Henderson DC, Fan X, Copeland PM, et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009;29:165-169.

    Google Scholar 

  68. Shafti SS. Augmentation of olanzapine by fluphenazine decanoate in poorly responsive schizophrenia. Clin Schizophr Relat Psychoses. 2009;3:97-102.

    Google Scholar 

  69. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol. 2004;19:23-26.

    Google Scholar 

  70. Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. 1999;39:81-85.

    Google Scholar 

  71. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3):CD006324.

    Google Scholar 

  72. Taylor DM, Smith L, Gee SH, Nielsen J. Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand. 2012;125:15-24.

    Google Scholar 

  73. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 2000;51:634-638.

    Google Scholar 

  74. Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv. 2002;53:1212.

    Google Scholar 

  75. Citrome L. Use of lithium, carbamazepine, and valproic acid in a state-operated psychiatric hospital. J Pharm Technol. 1995;11:55-59.

    Google Scholar 

  76. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009;9:55-71.

    Google Scholar 

  77. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109:10-14.

    Google Scholar 

  78. Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol. 2007;22:356-362.

    Google Scholar 

  79. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract. 2008;62:1237-1245.

    Google Scholar 

  80. Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011;37:921-929.

    Google Scholar 

  81. Citrome L, Volavka J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011;25:1009-1021.

    Google Scholar 

  82. Buckley P, Citrome L, Nichita C, Vitacco M. Psychopharmacology of aggression in schizophrenia. Schizophr Bull. 2011;37:930-936.

    Google Scholar 

  83. Nolan KA, Citrome L. Reducing inpatient aggression: does paying attention pay off? Psychiatr Q. 2008;79:91-95.

    Google Scholar 

  84. Grohmann R, Engel RR, Geissler KH, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry. 2004;37(suppl 1):S27-S28.

    Google Scholar 

  85. Xiang Y-T, Ungvari GS, Wang C-Y, et al. Adjunctive antidepressant prescriptions for hospitalized patients with schizophrenia in Asia (2001–2009). Asia Pac Psychiatry. Epub 29 Aug 2012.

    Google Scholar 

  86. Conley RR. The burden of depressive symptoms in people with schizophrenia. Psychiatr Clin North Am. 2009;32:853-861.

    Google Scholar 

  87. Makinen J, Miettunen J, Isohanni M, Koponen H. Negative symptoms in schizophrenia: a review. Nord J Psychiatry. 2008;62:334-341.

    Google Scholar 

  88. Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry. 2010;197:174-179.

    Google Scholar 

  89. Lieberman JA, Dunbar G, Segreti AC, et al. A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology. 2013. In press.

    Google Scholar 

  90. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-1047.

    Google Scholar 

  91. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012;25:96-102.

    Google Scholar 

  92. Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16:522-537.

    Google Scholar 

  93. Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10:275-287.

    Google Scholar 

  94. Umbricht D, Yoo K, Youssef E, et al. Investigational glycine transporter type 1 (GlyT1) inhibitor RG1678: results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Poster presented at: 49th Annual Meeting of the American College of Neuropsychopharmacology; December 5–9, 2010; Miami Beach, FL.

    Google Scholar 

  95. Kinon BJ, Gómez JC. Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013;66:82-86.

    Google Scholar 

  96. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107.

    Google Scholar 

  97. Kinon BJ, Zhang L, Millen BA, et al; and the HBBI Study Group. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349-355.

    Google Scholar 

  98. Lilly announces pomaglumetad methionil did not meet primary endpoint of clinical study [press release]. Eli Lilly and Company; July 11, 2012. newsroom.lilly.com/releasedetail. cfm?ReleaseID = 690836. Accessed March 19, 2013.

    Google Scholar 

  99. Lilly stops Phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results [press release]. Eli Lilly and Company; August 29, 2012. newsroom.lilly.com/releasedetail.cfm?ReleaseID = 703018. Accessed March 19, 2013.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA

    Leslie Citrome

Authors
  1. Leslie Citrome
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Citrome, L. (2013). Psychopharmacological Approaches. In: Handbook of Treatment-resistant Schizophrenia. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-88-3_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-908517-88-3_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-86-9

  • Online ISBN: 978-1-908517-88-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation